(CDAX, Technology, SYT GR)



Buy eur 8.90	(EUR 8.70)	Value Indicators: DCF: FCF-Value Potential 25e:	8.91	Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	2.3 3.0 3.8 0.0	Description: Soft- and hardware for data exchange for e.g. industrial pi and automotive electronics	lants
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2023e
		Market cap:	55.5	Freefloat	62.60 %	Beta:	1.3
Price	EUR 6.10	No. of shares (m):	9.1	Trier Asset Mgmt	22.40 %	Price / Book:	0.8 x
Upside	45.9 %	EV:	76.4	Alois Widmann	15.00 %	Equity Ratio:	54 %
		Freefloat MC:	34.8			Net Fin. Debt / EBITDA:	1.2 x
		Ø Trad. Vol. (30d):	23.28 th			Net Debt / EBITDA:	1.4 x

New contract increases visibility of profitable growth in Automotive

Softing has won a major order for a diagnostic system from a North American manufacturer of special vehicles. The contract has a volume of more than EUR 3m and includes license fees for the Softing TDX modular system, hardware for connecting the vehicles as well as maintenance and service contracts for five years. Softing expects positive cash flows of approx. EUR 1.5m as early as in Q1 2024.

We see this as an indication that the solid performance of Softing's traditional Automotive business in recent quarters will continue. After the first nine months of this year, sales in the traditional Automotive business grew by 17.6% to EUR 16.0m, while GlobalmatiX suffered from roll-out delays and burdened the profitability of the segment. The new contract and the catch-up effects in GlobalmatiX should enable the company to resume its high growth momentum and return the segment to profitability. Moreover, the increased installed base should generate highly profitable and recurring software and service revenues in subsequent years.

We have adjusted our estimates to better reflect the attractive prospects in Automotive, the already high profitability in Industrial, and a recovery in IT Networks after temporary production bottlenecks this year. Based on our updated forecast, we increase our target price from EUR 8.60 to EUR 8.90 and reiterate our Buy recommendation.


Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2023e (old)	+ / -	2024e (old)	+ / -	2025e (old)	+ / -	 Higher margin estimates for 2024 and 2025 reflect the attractive prospects in Automotive, the already high profitability in Industrial and a recovery in
Sales	115.7	0.0 %	120.7	0.5 %	128.1	0.9 %	IT Networks after temporary production disruptions
EBIT	6.1	0.0 %	6.0	22.1 %	8.6	3.8 %	
EBIT adj.	6.6	0.0 %	7.8	6.7 %	10.3	-0.7 %	

7.5 7.25 - Maylung	FY End: 31.12. in EUR m	CAGR (22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
7 -	Sales	9.5 %	91.1	77.6	84.7	98.3	115.7	121.3	129.2
6.75 -	Change Sales yoy		8.6 %	-14.8 %	9.1 %	16.1 %	17.7 %	4.8 %	6.5 %
6.5 - VV U VN N	Gross profit margin		62.9 %	59.5 %	58.2 %	54.9 %	58.5 %	58.0 %	57.8 %
6.25 - Mutra 400 M	EBITDA	23.3 %	12.1	7.8	9.1	9.7	15.2	16.3	18.2
6- W	Margin		13.3 %	10.0 %	10.7 %	9.9 %	13.2 %	13.4 %	14.1 %
5.75 - May monor and a	EBIT	127.1 %	4.3	-3.9	-0.5	0.8	6.1	7.3	8.9
5.5 - W 1 V W 1	Margin		4.7 %	-5.1 %	-0.6 %	0.8 %	5.3 %	6.0 %	6.9 %
5.25	EBIT adj.	46.2 %	3.9	1.6	3.0	3.3	6.6	8.3	10.2
5 -	Net income	-	2.8	-4.7	-0.3	-1.4	3.8	4.5	5.7
01/23 03/23 05/23 07/23 09/23 11/23	EPS	-	0.31	-0.52	-0.03	-0.15	0.42	0.50	0.63
Softing CDAX (normalised)	DPS	0.0 %	0.04	0.04	0.10	0.10	0.10	0.10	0.10
Rel. Performance vs CDAX:	Dividend Yield		0.5 %	0.7 %	1.6 %	1.7 %	1.6 %	1.6 %	1.6 %
	FCFPS		0.04	-0.38	0.42	-0.40	0.43	0.54	0.58
1 month: -10.1 %	FCF / Market cap		0.5 %	-6.5 %	6.9 %	-6.7 %	7.0 %	8.8 %	9.4 %
6 months: -18.1 %	EV / Sales		0.8 x	0.9 x	0.8 x	0.8 x	0.7 x	0.6 x	0.6 x
Year to date: 0.6 %	EV / EBITDA		6.3 x	9.0 x	7.7 x	7.7 x	5.0 x	4.6 x	4.0 x
Trailing 12 months: 3.8 %	EV / EBIT adj.		19.4 x	44.8 x	23.2 x	23.0 x	11.5 x	9.0 x	7.1 x
5	EV / EBIT		17.6 x	n.a.	n.a.	98.7 x	12.4 x	10.2 x	8.1 x
Company events:	P/E		24.8 x	n.a.	n.a.	n.a.	14.5 x	12.2 x	9.7 x
	FCF Potential Yield		5.9 %	4.8 %	6.2 %	6.1 %	8.7 %	9.6 %	11.6 %
	Net Debt		6.0	17.5	14.0	21.5	20.9	19.0	16.7
	ROCE (NOPAT)		4.0 %	n.a.	0.1 %	2.0 %	5.0 %	5.8 %	7.1 %
	Guidance:	Sales EUR 11	0-115m, adj.	EBIT EUR 6	.5m. EBIT El	JR 6.0m			

Analyst **Robert-Jan van der Horst** rvanderhorst@warburg-research.com +49 40 309537-290

WARBURG

Softing




Company Background

- Softing has the necessary expertise on information exchange between various devices, sensors, plant and software solutions in automated processes. Its business activity comprises three segments.
- Industrial Automation: hardware and software solutions for the exchange of information in all kinds of production including assembly lines, chemical plants, oil and gas extraction or refineries.
- IT Networks: diagnostic devices which are used in industrial automation and for the diagnosis of copper and optical fibre networks in data centers and office installations
- Automotive Electronics: The solutions allow engineers and workshop mechanics to test automotive electronics in the development phase, production or repair and to recognise errors via data evaluation.
- The solutions in the automotive segment are not for application within the vehicles and therefore do not pose a product re-call risk for the company.

Competitive Quality

- European market leader in the networking of various production plant elements as well as in business-related software (so-called OPC products).
- World market leader in components for the exchange of information in gas and oil plants. Some >50% of all devices registered worldwide that are used in these plants include components from Softing.
- Softing's participation in international committees that set standards for the exchange of information. This contributes to a short timeto-market.
- The high complexity of Softing's business activity is the single most important barrier to market entry for potential competitors.





DCF model Transitional period Term. Value Detailed forecast period Figures in EUR m 2023e 2024e 2025e 2026e 2027e 2028e 2029e 2030e 2031e 2032e 2033e 2034e 2035e Sales 115.7 121.3 127.6 133.9 140.1 146.3 152.4 158.5 164.5 170.5 176.3 182.0 185.7 Sales change 17.7 % 4.8 % 5.2 % 4.9 % 4.7 % 4.4 % 4.2 % 4.0 % 3.8 % 3.6 % 3.4 % 3.3 % 2.0 % 2.0 % EBIT 6.1 7.3 8.9 8.7 9.1 9.5 9.9 10.3 10.7 11.1 11.5 11.8 12.1 EBIT-margin 5.3 % 6.0 % 7.0 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % Tax rate (EBT) 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % NOPAT 4.3 5.1 6.2 6.1 6.4 6.7 6.9 7.2 7.5 7.8 8.0 8.3 8.4 Depreciation 91 90 93 98 10 1 10.4 10 7 10.9 110 11 1 10.9 11.3 11 5 in % of Sales 7.9 % 7.4 % 7.3 % 7.3 % 7.2 % 7.1 % 7.0 % 6.9 % 6.7 % 6.5 % 6.2 % 6.2 % 6.2 % 0.0 Changes in provisions 1.4 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Change in Liquidity from 1.2 1.2 - Working Capital 1.9 -0.2 0.6 1.6 1.2 1.2 1.1 11 1.1 1.1 0.8 - Capex 7.2 7.5 7.8 8.3 8.7 9.1 9.5 9.8 10.2 10.6 10.9 11.3 11.5 Capex in % of Sales 6.2 % 6.2 % 6.1 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % - Other 1.5 1.6 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Free Cash Flow (WACC 4.2 5.2 5.5 6.1 6.7 6.9 7.1 7.3 7.3 7.3 7.0 7.3 7.8 8 Model) PV of FCF 42 48 48 48 49 47 44 42 39 36 32 31 30 51 share of PVs 3.23 % 38.18 % 48.60 % Model parameter Valuation (m) Derivation of WACC: Derivation of Beta: Present values 2035e 54 51 **Terminal Value** Debt ratio 20.00 % Financial Strength 1.40 Financial liabilities 27 Cost of debt (after tax) 2.1 % Liquidity (share) 1.30 Pension liabilities 1 8.25 % 0 Market return Cyclicality 1.10 Hybrid capital Risk free rate 2.75 % Transparency 1.30 Minority interest 1 Others 1.30 Market val. of investments 0 Liquidity 5 No. of shares (m) 9.1 WACC 8.25 % Beta 1.28 81 Equity Value Value per share (EUR) 8.91

Sensitivity Value per Share (EUR)

		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1 .0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.51	9.3 %	6.95	7.08	7.22	7.36	7.51	7.68	7.86	1.51	9.3 %	4.94	5.75	6.55	7.36	8.17	8.97	9.78
1.39	8.8 %	7.59	7.74	7.90	8.08	8.27	8.47	8.69	1.39	8.8 %	5.49	6.35	7.22	8.08	8.94	9.81	10.67
1.34	8.5 %	7.94	8.11	8.29	8.48	8.69	8.92	9.16	1.34	8.5 %	5.79	6.69	7.58	8.48	9.38	10.27	11.17
1.28	8.3 %	8.32	8.50	8.70	8.91	9.15	9.40	9.68	1.28	8.3 %	6.12	7.05	7.98	8.91	9.85	10.78	11.71
1.22	8.0 %	8.72	8.92	9.15	9.38	9.65	9.93	10.24	1.22	8.0 %	6.47	7.44	8.41	9.38	10.35	11.32	12.29
1.17	7.8 %	9.15	9.38	9.63	9.90	10.19	10.51	10.86	1.17	7.8 %	6.86	7.87	8.88	9.90	10.91	11.92	12.93
1.05	7.3 %	10.14	10.42	10.73	11.07	11.44	11.85	12.30	1.05	7.3 %	7.75	8.85	9.96	11.07	12.17	13.28	14.39

• The cyclical components of the business activity and the low liquidity of the share raise capital costs.

Items in the "Others" line adjust for IFRS 16 depreciation on rights of use



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net Income before minorities	2.9	-4.6	-0.1	-1.2	4.0	4.8	5.9
+ Depreciation + Amortisation	7.8	11.7	9.5	9.0	9.1	9.0	9.3
- Net Interest Income	-0.1	-1.5	0.8	-1.3	-0.4	-0.5	-0.5
- Maintenance Capex	6.4	5.2	4.4	4.6	5.4	5.6	5.9
+ Other	0.0	0.0	0.0	0.0	-1.5	-1.5	-1.5
= Free Cash Flow Potential	4.4	3.4	4.3	4.6	6.6	7.1	8.3
FCF Potential Yield (on market EV)	5.9 %	4.8 %	6.2 %	6.1 %	8.7 %	9.6 %	11.6 %
WACC	8.25 %	8.25 %	8.25 %	8.25 %	8.25 %	8.25 %	8.25 %
= Enterprise Value (EV)	75.9	69.9	69.5	75.2	76.4	74.5	72.2
= Fair Enterprise Value	53.9	40.8	51.9	55.3	80.3	86.5	101.2
- Net Debt (Cash)	20.4	20.4	20.4	20.4	18.4	16.5	14.2
- Pension Liabilities	1.1	1.1	1.1	1.1	2.5	2.5	2.5
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of minorities 	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	32.4	19.3	30.4	33.8	59.4	67.5	84.5
Number of shares, average	9.1	9.1	9.0	9.0	9.0	9.0	9.0
= Fair value per share (EUR)	3.55	2.13	3.37	3.75	6.58	7.49	9.37
premium (-) / discount (+) in %					7.9 %	22.8 %	53.7 %
Sensitivity Fair value per Share (EUR)							
11.25 %	1.98	0.93	1.82	2.09	4.17	4.88	6.32
10.25 %	2.40	1.25	2.23	2.53	4.80	5.56	7.11
9.25 %	2.91	1.64	2.73	3.06	5.57	6.39	8.08
WACC 8.25 %	3.55	2.13	3.37	3.75	6.58	7.49	9.37
7.25 %	4.37	2.74	4.13	4.55	7.73	8.73	10.81
6.25 %	5.45	3.56	5.17	5.65	9.34	10.45	12.84
5.25 %	6.93	4.69	6.60	7.18	11.55	12.84	15.63

• Capitalised own work is a significant element of the capex.


• FCF-Value-CAGR 2019-2025e: 17%



Valuation 2019 2020 2021 2022 2023e 2024e 2025e Price / Book 1.0 x 0.8 x 0.9 x 0.9 x 0.8 x 0.8 x 0.8 x Book value per share ex intangibles 0.76 0.63 0.78 0.60 1.33 1.65 2.10 EV / Sales 0.8 x 0.9 x 0.8 x 0.8 x 0.7 x 0.6 x 0.6 x EV / EBITDA 6.3 x 5.0 x 4.6 x 4.0 x 9.0 x 7.7 x 7.7 x EV / EBIT 17.6 x 98.7 x 12.4 x 10.2 x 8.1 x n.a. n.a. EV / EBIT adj.* 44.8 x 23.2 x 23.0 x 19.4 x 11.5 x 9.0 x 7.1 x P / FCF 213.1 x 14.5 x 14.2 x 11.3 x 10.6 x n.a. n.a. P / E 24.8 x n.a. n.a. n.a. 14.5 x 12.2 x 9.7 x P / E adj.* 24.8 x n.a. 14.5 x 12.2 x 9.7 x n.a. n.a. **Dividend Yield** 0.5 % 0.7 % 1.6 % 1.7 % 1.6 % 1.6 % 1.6 % 6.2 % 4.8 % 6.1 % 8.7 % 9.6 % 11.6 % FCF Potential Yield (on market EV) 5.9 %

*Adjustments made for: Adj. figures exclude PPAs and changes to own work capitalized

Company Specific Items							
	2019	2020	2021	2022	2023e	2024e	2025e
order entries	n.a.	n.a.	104.8	102.9	0.0	n.a.	n.a.
book-to-bill	n.a.	n.a.	1.2	1.0	0.0	n.a.	n.a.
order book	n.a.	n.a.	33.6	38.2	0.0	n.a.	n.a.





In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Sales	91.1	77.6	84.7	98.3	115.7	121.3	129.2
Change Sales yoy	8.6 %	-14.8 %	9.1 %	16.1 %	17.7 %	4.8 %	6.5 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	5.5	3.7	3.7	3.9	5.4	4.9	4.7
Total Sales	96.6	81.3	88.3	102.3	121.1	126.2	133.9
Material expenses	39.3	35.1	39.1	48.3	53.5	55.8	59.2
Gross profit	57.3	46.1	49.3	53.9	67.6	70.4	74.7
Gross profit margin	62.9 %	59.5 %	58.2 %	54.9 %	58.5 %	58.0 %	57.8 %
Personnel expenses	35.4	31.7	33.6	36.0	39.9	41.3	43.7
Other operating income	0.8	1.7	2.8	3.7	0.6	1.0	1.2
Other operating expenses	10.5	8.4	9.4	11.9	13.1	13.8	14.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	12.1	7.8	9.1	9.7	15.2	16.3	18.2
Margin	13.3 %	10.0 %	10.7 %	9.9 %	13.2 %	13.4 %	14.1 %
Depreciation of fixed assets	2.6	2.2	2.2	1.7	2.4	2.4	2.5
EBITA	9.5	5.6	6.8	8.1	12.8	13.9	15.7
Amortisation of intangible assets	5.2	9.5	6.3	7.2	6.7	6.6	6.8
Goodwill amortisation	0.0	0.0	1.0	0.1	0.0	0.0	0.0
EBIT	4.3	-3.9	-0.5	0.8	6.1	7.3	8.9
Margin	4.7 %	-5.1 %	-0.6 %	0.8 %	5.3 %	6.0 %	6.9 %
EBIT adj.	3.9	1.6	3.0	3.3	6.6	8.3	10.2
Interest income	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Interest expenses	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Other financial income (loss)	0.3	-1.2	1.1	-1.0	0.0	0.0	0.0
EBT	4.2	-5.4	0.3	-0.6	5.7	6.8	8.4
Margin	4.7 %	-7.0 %	0.3 %	-0.6 %	5.0 %	5.6 %	6.5 %
Total taxes	1.3	-0.8	0.4	0.6	1.7	2.0	2.5
Net income from continuing operations	2.9	-4.6	-0.1	-1.2	4.0	4.8	5.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	2.9	-4.6	-0.1	-1.2	4.0	4.8	5.9
Minority interest	0.1	0.2	0.2	0.2	0.2	0.2	0.2
Net income	2.8	-4.7	-0.3	-1.4	3.8	4.5	5.7
Margin	3.1 %	-6.1 %	-0.3 %	-1.4 %	3.3 %	3.7 %	4.4 %
Number of shares, average	9.1	9.1	9.0	9.0	9.0	9.0	9.0
EPS	0.31	-0.52	-0.03	-0.15	0.42	0.50	0.63
EPS adj.	0.31	-0.52	-0.03	-0.15	0.42	0.50	0.63
*Adjustments made for: Adj. figures exclude PPAs and cha	ngoo to own wor	k oonitalizad					


Guidance: Sales EUR 110-115m, adj. EBIT EUR 6.5m. EBIT EUR 6.0m

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	92.8 %	94.7 %	93.6 %	94.1 %	91.5 %	90.6 %	89.5 %
Operating Leverage	0.6 x	n.a.	-9.6 x	n.a.	40.0 x	3.9 x	3.4 x
EBITDA / Interest expenses	44.4 x	29.8 x	36.0 x	34.5 x	50.8 x	54.3 x	60.8 x
Tax rate (EBT)	31.0 %	15.5 %	123.9 %	-109.4 %	30.0 %	30.0 %	30.0 %
Dividend Payout Ratio	12.4 %	n.m.	n.m.	n.m.	22.4 %	18.9 %	15.3 %
Sales per Employee	225,416	195,458	218,273	248,889	272,235	285,412	304,000


Operating Performance

Sales, EBITDA in EUR m



in %

Performance per Share



COMMENT Published 13.12.2023

6

Consolidated balance sheet



80 %

70 %

60 %

50 %

40 %

30 %

20 %

10 %

0 %


2024e

2025e

In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Assets							
Goodwill and other intangible assets	62.4	56.8	55.8	55.6	54.2	53.1	52.0
thereof other intangible assets	27.7	20.7	20.2	18.7	16.7	14.7	12.7
thereof Goodwill	18.1	17.5	17.1	17.4	17.4	17.4	17.4
Property, plant and equipment	3.2	5.5	4.8	7.6	8.6	9.8	11.0
Financial assets	1.5	1.5	1.5	0.4	0.4	0.4	0.4
Other long-term assets	2.8	0.0	0.0	0.0	9.0	9.0	9.0
Fixed assets	69.9	63.8	62.1	63.6	72.2	72.3	72.4
Inventories	12.6	13.7	13.4	19.0	19.6	19.6	19.9
Accounts receivable	15.4	14.3	14.1	16.8	19.3	19.9	20.9
Liquid assets	14.9	10.2	9.6	6.8	7.9	9.8	12.1
Other short-term assets	4.0	3.2	4.2	4.3	4.3	4.3	4.3
Current assets	46.9	41.4	41.3	46.8	51.1	53.6	57.2
Total Assets	116.8	105.2	103.4	110.4	123.3	125.9	129.6
Liabilities and shareholders' equity							
Subscribed capital	9.1	9.1	9.1	9.1	9.1	9.1	9.1
Capital reserve	31.1	31.1	31.1	31.1	31.1	31.1	31.1
Retained earnings	29.1	22.9	23.2	21.3	25.1	29.6	35.3
Other equity components	0.0	-0.5	-0.5	-0.5	1.0	-1.7	-4.4
Shareholders' equity	69.3	62.6	62.9	61.0	66.3	68.1	71.1
Minority interest	0.3	0.4	0.6	0.8	0.8	0.8	0.8
Total equity	69.6	63.0	63.5	61.8	67.1	69.0	71.9
Provisions	4.4	3.2	2.8	1.2	5.4	5.4	5.4
thereof provisions for pensions and similar obligations	3.1	3.1	2.6	1.1	2.5	2.5	2.5
Financial liabilities (total)	17.8	24.6	21.0	27.2	26.3	26.3	26.3
Short-term financial liabilities	1.6	4.7	3.5	5.5	5.0	5.0	5.0
Accounts payable	6.5	6.0	7.2	9.3	10.5	11.3	12.0
Other liabilities	18.4	8.4	8.8	11.0	14.0	14.0	14.0
Liabilities	47.2	42.2	39.8	48.6	56.2	57.0	57.7
Total liabilities and shareholders' equity	116.8	105.2	103.4	110.4	123.3	125.9	129.6

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	4.1 x	3.1 x	3.9 x	3.4 x	3.6 x	3.7 x	3.7 x
Capital Employed Turnover	1.2 x	1.0 x	1.1 x	1.2 x	1.3 x	1.4 x	1.5 x
ROA	4.0 %	-7.4 %	-0.4 %	-2.2 %	5.3 %	6.3 %	7.8 %
Return on Capital							
ROCE (NOPAT)	4.0 %	n.a.	0.1 %	2.0 %	5.0 %	5.8 %	7.1 %
ROE	4.1 %	-7.2 %	-0.4 %	-2.3 %	6.0 %	6.8 %	8.2 %
Adj. ROE	4.1 %	-7.2 %	-0.4 %	-2.3 %	6.0 %	6.8 %	8.2 %
Balance sheet quality							
Net Debt	6.0	17.5	14.0	21.5	20.9	19.0	16.7
Net Financial Debt	2.9	14.4	11.4	20.4	18.4	16.5	14.2
Net Gearing	8.6 %	27.7 %	22.0 %	34.8 %	31.1 %	27.5 %	23.2 %
Net Fin. Debt / EBITDA	24.2 %	185.7 %	125.4 %	209.4 %	120.7 %	100.9 %	77.7 %
Book Value / Share	7.6	6.9	6.9	6.7	7.3	7.5	7.8
Book value per share ex intangibles	0.8	0.6	0.8	0.6	1.3	1.7	2.1



Published 13.12.2023

7

Consolidated cash flow statement




In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net income	2.9	-4.6	-0.1	-1.2	4.0	4.8	5.9
Depreciation of fixed assets	2.6	2.2	2.2	1.7	2.4	2.4	2.5
Amortisation of goodwill	0.0	0.0	1.0	0.1	0.0	0.0	0.0
Amortisation of intangible assets	5.2	9.5	6.3	7.2	6.7	6.6	6.8
Increase/decrease in long-term provisions	0.0	0.0	-0.1	-0.5	1.4	0.0	0.0
Other non-cash income and expenses	1.5	-1.8	-0.2	3.0	0.0	0.0	0.0
Cash Flow before NWC change	12.2	5.3	9.2	10.3	14.5	13.8	15.2
Increase / decrease in inventory	-2.0	-1.1	0.3	-5.6	-0.6	0.0	-0.3
Increase / decrease in accounts receivable	-1.7	1.2	0.4	-2.9	-2.5	-0.6	-1.0
Increase / decrease in accounts payable	0.0	-0.5	1.2	2.0	1.2	0.8	0.7
Increase / decrease in other working capital positions	1.8	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-1.9	-0.4	1.9	-6.4	-1.9	0.2	-0.6
Net cash provided by operating activities [1]	10.4	4.9	11.1	3.8	12.6	14.0	14.6
Investments in intangible assets	-7.4	-5.4	-4.8	-5.1	-5.3	-5.5	-5.7
Investments in property, plant and equipment	-1.1	-1.5	-1.5	-4.9	-1.9	-2.0	-2.1
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	-1.5	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-8.5	-8.5	-5.9	-6.1	-7.2	-7.5	-7.8
Change in financial liabilities	6.5	1.1	-4.2	1.6	-0.9	0.0	0.0
Dividends paid	-1.2	-0.4	-0.4	-0.9	-0.9	-0.9	-0.9
Purchase of own shares	0.0	-0.5	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-1.9	-1.4	-1.3	-1.4	-2.5	-3.6	-3.6
Net cash provided by financing activities [3]	3.4	-1.1	-5.9	-0.7	-4.3	-4.5	-4.5
Change in liquid funds [1]+[2]+[3]	5.3	-4.7	-0.7	-3.0	1.1	2.0	2.3
Effects of exchange-rate changes on cash	0.0	-0.1	0.2	0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	14.9	10.2	9.6	6.8	7.9	9.8	12.1

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
	2019	2020	2021	2022	20236	20246	20256
Cash Flow							
FCF	0.3	-3.4	3.8	-3.6	3.9	4.9	5.2
Free Cash Flow / Sales	0.4 %	-4.4 %	4.5 %	-3.7 %	3.3 %	4.0 %	4.0 %
Free Cash Flow Potential	4.4	3.4	4.3	4.6	6.6	7.1	8.3
Free Cash Flow / Net Profit	11.7 %	72.2 %	-1501.6 %	258.2 %	101.9 %	107.0 %	91.5 %
Interest Received / Avg. Cash	0.5 %	0.4 %	0.3 %	0.6 %	0.5 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	1.8 %	1.2 %	1.1 %	1.2 %	1.1 %	1.1 %	1.1 %
Management of Funds							
Investment ratio	9.3 %	9.0 %	7.5 %	10.1 %	6.2 %	6.2 %	6.0 %
Maint. Capex / Sales	7.0 %	6.7 %	5.2 %	4.6 %	4.7 %	4.6 %	4.5 %
Capex / Dep	108.5 %	59.6 %	66.1 %	111.1 %	79.1 %	83.3 %	83.9 %
Avg. Working Capital / Sales	20.3 %	24.6 %	21.3 %	19.5 %	19.4 %	19.2 %	18.2 %
Trade Debtors / Trade Creditors	237.5 %	238.7 %	194.7 %	180.9 %	183.8 %	176.1 %	174.2 %
Inventory Turnover	3.1 x	2.6 x	2.9 x	2.5 x	2.7 x	2.8 x	3.0 x
Receivables collection period (days)	62	67	61	62	61	60	59
Payables payment period (days)	60	62	67	70	72	74	74
Cash conversion cycle (Days)	94	119	86	98	89	81	77





Free Cash Flow Generation

Published 13.12.2023

Working Capital

25.0 %

22.5 %

20.0 %

17.5 %

15.0 %

12.5 %

10.0 %

7.5 %

5.0 %

2.5 %

0.0 %

2025e



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)	
Softing	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005178008.htm	



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	154	73
Hold	45	21
Sell	6	3
Rating suspended	7	3
Total	212	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	44	81
Hold	7	13
Sell	0	0
Rating suspended	3	6
Total	54	100

PRICE AND RATING HISTORY SOFTING AS OF 13.12.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Hannes Müller Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270	Andreas Pläsier Banks. Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Stefan Augustin	hrueschmeier@warburg-research.com +49 40 309537-168	Malte Schaumann	+49 40 309537-170
Cap. Goods, Engineering	saugustin@warburg-research.com	Technology	mschaumann@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155	Oliver Schwarz	+49 40 309537-250
Christian Cohrs	jbauer@warburg-research.com +49 40 309537-175	Chemicals, Agriculture Simon Stippig	oschwarz@warburg-research.com +49 40 309537-265
Industrials & Transportation	ccohrs@warburg-research.com	Real Estate, Telco	sstippig@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290
Software, IT Jörg Philipp Frey	fellmann@warburg-research.com +49 40 309537-258	Technology Andreas Wolf	rvanderhorst@warburg-research.com +49 40 309537-140
Retail, Consumer Goods	jfrey@warburg-research.com	Software, IT	awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185		
Financial Services	mfuhrberg@warburg-research.com +49 40 309537-240		
Automobiles, Car Suppliers	fhoelscher@warburg-research.com		
Philipp Kaiser	+49 40 309537-260		
Real Estate, Construction Thilo Kleibauer	pkaiser@warburg-research.com +49 40 309537-257		
Retail, Consumer Goods	tkleibauer@warburg-research.com		
INSTITUTIONAL EQUI	TY SALES		
Marc Niemann	+49 40 3282-2660	Rudolf Alexander Michaelis	+49 40 3282-2649
Head of Equity Sales, Germany	mniemann@mmwarburg.com +49 40 3282-2665	Germany	rmichaelis@mmwarburg.com +49 69 5050-7412
Tim Beckmann United Kingdom	tbeckmann@mmwarburg.com	Roman Alexander Niklas Switzerland	rniklas@mmwarburg.com
Lea Bogdanova	+49 69 5050-7411		
United Kingdom, Ireland	lbogdanova@mmwarburg.com	Antonio Mällon	
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com	Antonia Möller Roadshow/Marketing	+49 69 5050-7417 amoeller@mmwarburg.com
Matthias Fritsch	+49 40 3282-2696	Charlotte Wernicke	+49 40 3282-2669
United Kingdom	mfritsch@mmwarburg.com	Roadshow/Marketing	cwernicke@mmwarburg.com
Maximilian Martin	+49 69 5050-7413	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694
Austria, Poland	mmartin@mmwarburg.com	5	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOR	
Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com	Marcel Magiera Designated Sponsoring	+49 40 3282-2662 mmagiera@mmwarburg.com
Rico Müller	+49 40 3282-2685	Sebastian Schulz	+49 40 3282-2631
Sales Trading	rmueller@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast	+49 40 3282-2701	Jörg Treptow	+49 40 3282-2658
Sales Trading MACRO RESEARCH	bquast@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439
Macro Research	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com
Our research can be f	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	Refinitiv	www.refinitiv.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta			
Andrea Schaper Sales Assistance	+49 40 3282-2632	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthia@mmwarburg.com
Gaics Assistance	aschaper@mmwarburg.com	00153 A3315101168	kmuthig@mmwarburg.com